
Newly reported findings from a randomized phase III vaccine efficacy trial demonstrate that HPV vaccination may offer protection against HPV-related cancers across multiple tumor sites in women aged 18-25 who had been previously exposed to the human papillomavirus, with the vaccine effective in more than half of these women.
























